“Our momentum in the second quarter continued to reflect our strong operational execution and broadening portfolio with the addition of our Enhanced Brain Delivery program,” said Daniel O’Connell, Chief Executive Officer of Acumen (ABOS). “We purposely pursued this collaboration to augment our pipeline with innovative science in a fiscally responsible manner, all with the goal of delivering meaningful impact to patients. We look forward to producing a non-clinical data package in early 2026 that will further inform our EBD development strategy. This will be closely followed by expected topline results in late 2026 for ALTITUDE-AD, our Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD. We believe, with this portfolio, that we are well-positioned to deliver next-generation treatment options for early Alzheimer’s disease.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS:
- ABOS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Acumen Pharmaceuticals’ Promising Alzheimer’s Study: A Potential Game-Changer?
- Acumen presents results from its Phase 2 ALTITUDE-AD study of sabirnetug
- Strategic Buy Rating for Acumen Pharmaceuticals: Leveraging JCR Collaboration to Enhance Asset Delivery and Differentiation
- Acumen Pharmaceuticals Partners with JCR for Alzheimer’s Treatment